Safety and Efficacy of Gliflozin Group Among Patients with Type 2 Diabetes Including Patient’s Satisfaction in Saudi Arabia
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2019, Vol 18, Issue 4
Abstract
Introduction: Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors is the newest class of oral hypoglycemic agents that was approved for the management of patients with T2DM. Gliflozin group (Empagliflozin, Dapagliflozin & Canagliflozin) have a unique mechanism of action in reducing hyperglycemia by decreasing renal glucose reabsorption and promoting urinary glucose excretion. The aim of this research is to monitor and evaluate the clinical efficacy and safety of (SGLT2) inhibitors for the treatment of type 2 diabetes. Methodology: This study is a prospective cohort study supported by a questionnaire conducted by patients’ interview. Patients’ lab results were taken at baseline and 3-6 months later. This study, also, compared between two groups of patients; (26 patients) on Dapagliflozin and (23 patients) on Empagliflozin to compare the difference between their effects on HbA1c, FBG, Weight, BMI, LDL, HDL, TG, and total cholesterol. Result: Treatment with gliflozin group resulted in a significant reduction on HbA1c by (1%), FBG by (2.77 mmol/l) and BMI by (0.56 kg/m2 ) over 3 to 6 months. On the other hand, there was no significant difference in the comparison between Dapagliflozin and Empagliflozin group. During Ramadan month (46.2%) of the patients were very satisfied by the effect of gliflozin group, furthermore, no serious side effects were reported this month. Conclusion: Gliflozin group was generally well tolerated, no serious side effect or hypoglycemic events have been reported during or after Ramadan. Empagliflozin have a favorable effect in reducing HbA1c and FBG over Dapagliflozin. However, Dapagliflozin has a better influence on weight reduction.Subject of this study are susceptible to hypoglycemia especially in Ramadan month or fasting days. Also, the rate of night urination in this population is higher which may make them more liable to volume depletion. Additionally, type 2 diabetes patients need to manage their weight to maintain a good glucose control. Compliance and tolerance are always a challenge in patients with chronic disease. Gliflozin group have the following characteristics: a. Less hypoglycemic side effect; b. A positive effect on weight reduction; c. Help in controlling the glucose level; d. Tolerable with no serious side effects. Empagliflozin have a favor effect in reducing HbA1c and FBG over Dapagliflozin. However, Dapagliflozin have a better influence on weight reduction in comparison to Empagliflozin. During Ramadan month (46.2%) of the patients were very satisfied from the effect of gliflozin group. Due to the unique properties of gliflozin group in weight reduction and low risk of hypoglycemia, all these findings make gliflozin group a better choice for obese patients and who are at risk of hypoglycemia. Therefore, in comparison to other hypoglycemic agents as sulfonylureas and insulin therapy, which induce hypoglycemia and weight gain, consider the best option in diabetes treatment.
Authors and Affiliations
Al Hejji R, Al Ghamdi M, Al Haqbani D, Al Anazi B, Al Bajjal S, Al Ghadeer A, Al Najjar A, Al Suwaidan S
Keywords
Related Articles
- EP ID EP621855
- DOI 10.26717/BJSTR.2019.18.003173
- Views 148
- Downloads 0
Endometrial sarcoma. Case report and review of the literature
Endometrial stromal sarcoma is a rare type of endometrial cancer that is mainly present in older women. There is no specific classification for this type of endometrial cancer and for this reason we use the FIGO classifi...
Is there a Low Risk of Multiple Sclerosis in HIV Patients?
Objective: Discuss the hypothesis of HIV infection to reduce the risk of Multiple Sclerosis. Method: Non-systematic review using a Google Scholar platform of articles with the keywords: “HIV” or “Human Immunodeficiency V...
Hepatitis C - Chronic Disease Early Diagnosis and Socioeconomic Impact
Hepatitis C is an infection caused by the virus (HCV) discovered in the late 1980s. It is a silent disease that at first does not produce symptoms and can take years until its detection. Currently, 160 million people wor...
Evaluation of Physical Activity in a Group of Physically Inactive Individuals from a Government Corporation
Modern societies are undergoing considerable changes, such as the increase of physical inactivity. Epidemiological and scientific studies report that physical activity is related to reduced morbidity and mortality fr...
Granulomatosis with Polyangiitis with Intestinal Perforations as Complications: Case Report
Granulomatosis with Polyangiitis (GPA) is a systemic vasculitis which clinical manifestations are diverse, usually it shows involvement in pulmonary and nephrological level. The clinical case of a 36 years old male with...